Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

OUS Approvals Analysis: Expanded CoreValve Indication And Zika IVDs Among August’s CE Marks

Executive Summary

August was another slow month for announcements of medical device approvals outside the US, but the short list of non-US approvals this month includes a broad range of device-types approved, notably a much-awaited expanded indication for Medtronic’s CoreValve Evolut R, in six different territories.


Related Content

Zika Assay Reviews Are Testing The Limits Of FDA Capacity, Shuren Says
US FDA Approves First Intermediate-Risk Indication For TAVR
Expanded Indication For Edwards’ Sapien 3 Squarely In Sight
Data And More Data Expected To Drive BTG Towards Triple-Growth Target
Neuro Medtech Investors Have Time (And Money) For The Pain
APPROVALS ANALYSIS: Big Jump In CE Marks, But Slow August For PMAs
BTG snaps up Biocompatibles


Related Companies